Trade names Baxdela CAS Number 189279-58-1 Molar mass 440.76 g/mol | Legal status Investigational PubChem CID 487101 | |
 | ||
Routes ofadministration Oral, intravenous injection Synonyms ABT-492; RX-3341; WQ-3034 | ||
How to pronounce delafloxacin
Delafloxacin (INN) (tentative brand name Baxdela; former developmental code names ABT-492, RX-3341, WQ-3034), as the meglumine salt delafloxacin meglumine (USAN), is a fluoroquinolone antibiotic that is under development by Melinta Therapeutics (formerly Rib-X Pharmaceuticals) for the treatment of bacterial infections. As of December 2016, it is in Phase III clinical trials in the United States.
Contents
Delafloxacin is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections.
Clinical trials
Phase II clinical trials have been completed, including a trial with tigecycline as a comparator The company states delafloxacin met its primary and secondary efficacy endpoints based on the draft guidance from the FDA.
A Phase III trial for acute bacterial skin and skin structure infections (ABSSSI) is due to begin in the 2nd half of 2012.